Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

EMA approves WELIREG® (belzutifan) for advanced clear cell RCC that progressed following a PD(L)-1 inhibitor and at least two VEGF therapies

February 25, 2025

EPKINLY® (epcoritamab) Approved by Japan MHLW for Additional Indication as a Treatment for R/R Follicular Lymphoma

February 25, 2025

U.S. FDA Approves ADCETRIS Combination Regimen for the treatment of R/R DLBCL

February 19, 2025

Serplulimab Approved in the EU for 1L Treatment of ES-SCLC

February 11, 2025

Enhertu approved in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies

February 5, 2025

NMPA approves Sarclisa + SOC VRd in China for patients with newly diagnosed multiple myeloma ineligible for transplant

February 4, 2025

Tagitanlimab Approved by NMPA in Combination with Cisplatin and Gemcitabine For the 1L Treatment of Patients with recurrent or metastatic NPC

January 28, 2025

FDA Approves Lumakras® (Sotorasib) + Vectibix® (Panitumumab) For Chemorefractory KRAS G12C-Mutated Metastatic CRC

January 21, 2025

Calquence plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma

January 21, 2025

European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer

January 21, 2025

Datroway (datopotamab deruxtecan) approved in the US for patients with previously treated metastatic HR+ve, HER2-neg breast cancer

January 21, 2025

DATROWAY Approved in Japan for Patients with Previously Treated Unresectable or Recurrent HR+ve, HER2neg Breast Cancer

January 7, 2025

European Commission approves RYBREVANT (amivantamab) + LAZCLUZE (lazertinib) for the 1L treatment of patients with EGFR-mutated advanced NSCLC

January 7, 2025

China’s NMPA Approves VYLOYTM (zolbetuximab) for 1L Treatment of Advanced Gastric or GEJ Adenocarcinoma

January 7, 2025

TEVIMBRA Approved in US for 1L Treatment of Gastric and GEJ Cancers in Combination with Chemotherapy

December 31, 2024

EC approves Opdivo + Yervoy for the 1L Treatment of Adult Patients with MSI-H or dMMR Metastatic CRC

December 31, 2024

US FDA Approves SC Opdivo Qvantig (nivolumab & hyaluronidase-nvhy) Injection in Most Previously Approved Adult, Solid Tumor Opdivo Indications

December 31, 2024

FDA approves Itovebi for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

December 26, 2024

FDA approves ensartinib for ALK-positive locally advanced or metastatic NSCLC

December 26, 2024

U.S. FDA Approves BRAFTOVI Combination Regimen as 1L Treatment of BRAF V600E-Mutant mCRC

December 25, 2024

Tagrisso approved in the EU for patients with unresectable EGFR-mutated lung cancer

December 25, 2024

FDA Approves UNLOXCYT™ (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma

December 18, 2024

Neoadjuvant KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemo, Then Continued as Monotherapy as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC

December 17, 2024

Imfinzi approved in the US for patients with limited-stage small cell lung cancer

December 10, 2024

FDA Approves BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ NSCLC Based on Safety and Efficacy Data From the eNRGy Study

December 10, 2024
Page1 Page2 Page3 Page4 … Page11

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.